An international, specialty pharmaceutical company focused on improving existing drugs by incorporating its proprietary, advanced controlled-release technologies.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
A nice Canadian biotech company with moderate near-term profit potential. The stock has been beaten way down in the past month because of a 2nd 'approvable' letter from the FDA regarding tramadol. But tramadol just gained approval in Canada, and I anticipate that they'll eventually get this through the FDA as well. When it does, you can expect an instant 300% profit. Meanwhile, the stock sits at a point too damn low for a company with DDSS's potential. Even while the market waits to see what the result of talks with the FDA are, I expect a healthy correction back into the $4.00 range. While the company remains partially under the radar, it was just raised from 'sell' to 'hold' by one of the few analysts.